AI Science Tracker

popEVE: diagnosing rare developmental disorders

Harvard Medical School · 24 Nov 2025 · medicine

Discovery

popEVE: diagnosing rare developmental disorders

Applied to about 30,000 patients with severe undiagnosed developmental disorders, it led to a diagnosis in about one-third of cases and identified variants in 123 previously unknown genes, 25 of which were independently confirmed by other labs. This is preliminary clinical use; further checks are needed before adoption, and the page gives no detailed metrics.

Technology: popEVE (variant-effect prediction model)

Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: prospective or independent check
  • Tested: popEVE was tested on documented variants and case studies, and applied to about 30,000 undiagnosed patients, leading to a diagnosis in about one-third; 123 novel gene candidates were identified, and 25 were independently confirmed by other labs.
  • Still unknown: The press article says popEVE will need further verification for safety and accuracy before wide clinical adoption, and gives no accuracy metrics; it is not yet in routine clinical use.
  • AI role: A deep generative model extending EVE with a protein language model, producing a calibrated disease-likelihood score for each variant.

Evidence sources: https://hms.harvard.edu/news/new-artificial-intelligence-model-could-speed-rare-disease-diagnosis · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41588-025-02400-1&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 4/5 · Validation 4/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.